Skip to main content

Lumasiran Side Effects

Medically reviewed by Last updated on Jun 19, 2023.

Applies to lumasiran: subcutaneous solution.

Serious side effects of Lumasiran

Along with its needed effects, lumasiran may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Other side effects of Lumasiran

Some side effects of lumasiran may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to lumasiran: subcutaneous solution.


The most common side effect reported was injection site reactions.[Ref]


Very common (10% or more): Abdominal pain (included abdominal pain, upper abdominal pain, lower abdominal pain, abdominal discomfort, abdominal tenderness; up to 15%)[Ref]


Common (1% to 10%): Anti-drug antibodies[Ref]

Anti-drug antibody titers were low and generally transient. No clinically significant differences in efficacy, safety, pharmacokinetic, or pharmacodynamic profiles of this drug were observed in patients who tested positive for anti-drug antibodies.[Ref]


Very common (10% or more): Injection site reaction (included injection site reaction, injection site erythema, injection site pain, injection site pruritus, injection site swelling, injection site discomfort, injection site discoloration, injection site mass, injection site induration, injection site rash, injection site bruising, injection site hematoma, injection site exfoliation; up to 38%)[Ref]

During clinical studies, injection site reactions occurred in 10% of injections. The most commonly reported symptoms included erythema, pain, pruritus, and swelling. Injection site reactions were generally mild, resolved within 2 days, and did not lead to interruption/discontinuation of therapy.[Ref]


1. (2021) "Product Information. Oxlumo (lumasiran)." Alnylam UK Ltd

2. (2022) "Product Information. Oxlumo (lumasiran)." Alnylam Pharmaceuticals

3. EMEA. European Medicines Agency (2007) EPARs. European Union Public Assessment Reports.

4. (2020) "Product Information. Oxlumo (lumasiran)." Alnylam Pharmaceuticals

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.